Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy

Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 and PARP3 enzymes. Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma, with both BRCA -mutated (germline and somatic...

Full description

Bibliographic Details
Main Authors:	Graziela Z. Dal Molin, Kohei Omatsu, Anil K. Sood, Robert L. Coleman
Format:	Article
Language:	English
Published:	SAGE Publishing 2018-06-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/1758835918778483

Similar Items

Emerging treatment options for ovarian cancer: focus on rucaparib
by: Mariappan L, et al.
Published: (2017-12-01)

Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
by: Pearre DC, et al.
Published: (2018-11-01)

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status
by: Sayeh Saravi, et al.
Published: (2021-09-01)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018-03-01)

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
by: Dockery LE, et al.
Published: (2017-06-01)

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
by: Olga Kondrashova, et al.
Published: (2018-09-01)

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
by: Elizabeth M. Swisher, et al.
Published: (2021-05-01)

Pre-clinical imaging evaluation of the PARP inhibitor rucaparib
by: Almeida, Gilberto Serrano de
Published: (2013)

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
by: P. Grivas, et al.
Published: (2021-05-01)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
by: Audrey Laroche, et al.
Published: (2017-04-01)

Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting
by: Laura Tookman, et al.
Published: (2020-05-01)

Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer
by: Justin A. Harold, et al.
Published: (2018-11-01)

The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity
by: Nicola J Curtin
Published: (2020-02-01)

Safety and Efficacy of Hypoglycemic Therapy: Place of Metformin
by: K.A. Zuyev, et al.
Published: (2013-10-01)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
by: Shaolu Zhang, et al.
Published: (2021-05-01)

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
by: Maitri Kalra, et al.
Published: (2021-03-01)

Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy
by: Tiziana Vavalà, et al.
Published: (2018-08-01)

The Baerveldt Glaucoma Drainage Device: Efficacy, Safety, and Place in Therapy
by: Poelman HJ, et al.
Published: (2020-09-01)

Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy
by: Kae Nakamura, et al.
Published: (2021-03-01)

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
by: Dima D, et al.
Published: (2020-08-01)

Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy
by: Kongara K, et al.
Published: (2018-08-01)

Synthetic curcumin: An update on efficacy and safety
by: Roopesh Jain, et al.
Published: (2016-01-01)

Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety
by: Ni J, et al.
Published: (2020-10-01)

Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
by: Marin J, et al.
Published: (2018-05-01)

Stereoelectroencephalography in epilepsy, cognitive neurophysiology, and psychiatric disease: safety, efficacy, and place in therapy
by: Youngerman BE, et al.
Published: (2019-06-01)

Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety
by: Erminia Ridolo, et al.
Published: (2015-04-01)

Update on the safety and efficacy of teriparatide in the treatment of osteoporosis
by: Salvatore Minisola, et al.
Published: (2019-10-01)

Long-term efficacy and safety of iloperidone: an update
by: Rado JT, et al.
Published: (2014-02-01)

Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy
by: Emma Kipps, et al.
Published: (2017-03-01)

An updated review of the efficacy of cupping therapy.
by: Huijuan Cao, et al.
Published: (2012-01-01)

Efficacy and Safety of Stem Cell Therapy for T1DM: An Updated Systematic Review and Meta-Analysis
by: Shi-Yi Sun, et al.
Published: (2020-01-01)

An update on the efficacy and safety of aclidinium bromide in patients with COPD
by: Khuder Alagha, et al.
Published: (2011-02-01)

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
by: Jacqueline S Garcia, et al.
Published: (2010-02-01)

The Efficacy And Safety Of Aspirin As The Primary Prevention Of Cardiovascular Disease: An Updated Meta-Analysis
by: Xie W, et al.
Published: (2019-09-01)

Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy
by: Tarantino N, et al.
Published: (2017-02-01)

Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
by: Sunakawa Y, et al.
Published: (2017-09-01)

An Update on Ovarian Aging and Ovarian Reserve Tests
by: Ramazan Amanvermez, et al.
Published: (2016-01-01)

Update on the efficacy, effectiveness and safety of artemether&ndash;lumefantrine combination therapy for treatment of uncomplicated malaria
by: Pauline Byakika-Kibwika, et al.
Published: (2009-12-01)

Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China
by: Jing Ni, et al.
Published: (2019-11-01)

Reevaluation and update on efficacy and safety of neostigmine for reversal of neuromuscular blockade
by: Luo J, et al.
Published: (2018-12-01)